Please note that all agenda timings are Eastern Time. For PDT time and full session descriptions download the full program details here

8:30 am Virtual Coffee & Registration

8:50 am Chair’s Opening Remarks

Repurposing and Repositioning For Infectious Diseases Including Covid-19

9:00 am Panel Discussion – Repurposing Prominence During Covid-19


Drug repurposing has shone during the pandemic, but will the lessons learned translate into a more
organized response for future pandemics?

9:45 am Case Study – The Powerful Impact of Artificial Intelligence on SARS-CoV-2 Drug Repurposing Efforts


• Why AI and machine learning models are necessary to repurpose drugs in response to Covid-19
• Leveraging AI technology is providing promising repurposing results
• Drug repurposing has an exciting future, with further successful AI models for repurposing to come

10:15 am Case Study – Putting Machine Learning Models into Large Scale Production for Drug Discovery


• Overview of Machine Learning in a production drug discovery pipeline
• A case-study in rapid COVID repurposing screening
• Deep-dive into generalizable industrialized drug discovery

10:45 am Virtual Speed Networking & Morning Break

11:15 am Case Study – The Role Repurposing Can Play in Covid-19 & Other Infectious Diseases


• Learning from repurposing in other infectious disease areas
• Exploring the advantages and limitations of drug repurposing
• Overview of different AI approaches in repurposing for Covid-19
• Steps to gauge if a potential repurposing project is worth actioning – balancing development and commercial risk

11:45 am Using The Biological Insight Knowledge Graph to Repurpose Therapeutic Assets for Covid-19


• Repurposing as a response to the pandemic
• Knowledge graphs as a natural way to automate feature engineering for AI
• Leveraging AI with knowledge graphs to accelerate discovery and triaging of assets

Impact of AI-Driven Drug Repurposing in Oncology, Rare & Infectious Disease

12:15 pm Case Study – AI-Powered Drug Repurposing For Rare Diseases

  • Ian Roberts Director of Therapeutic Technology, Healx


• Healx combines AI with drug discovery expertise to find novel treatments for the 400 million people living with a rare disease. 95% of those conditions do not have an approved treatment
• Using an innovative AI platform, Healx makes drug development faster and more efficient by identifying potential opportunities to repurpose existing drugs
• This approach has already shown success with Fragile X syndrome, a rare genetic condition. Join Dr Ian Roberts to learn more

12:45 pm Exploring New Tools for Remote Collaborative Structural Based Drug Design

1.00 pm Networking Lunch


Lunchtime Workshop
Artificial Intelligence, Drug Repurposing & Covid-19
From the onset of Covid-19, organizations from many different backgrounds have been quick to transition resources and apply their artificial intelligence expertise across the full spectrum of drug discovery and development. It is clear artificial intelligence and machine learning can play a large role in overcoming the crisis by enabling the medical community, policy makers, and general public with the right tools to manage every stage of the crisis; from detection, prevention and response, to recovery and accelerating research and treatment efforts.

This workshop details drug repositioning efforts in finding candidates with the optimal profile for clinical success.

Topics of Discussion Include:

• Discussing ML and its use to identify biological targets for therapeutic intervention in heterogeneous disease and find suitable drug candidates that bind those targets
• Machine learning models for estimating small molecule activity from molecular structure, for a range of SARS-CoV-2 related assays

2:00 pm Case Study – Using Machine Learning & Artificial Intelligence to Discover Repurposed Rare & Orphan Disease Drug Candidates

  • Steve Smith Principal Computational Biology Data Scientist, Teva Pharmaceuticals


• Why drug repurposing in rare and orphan disease research can benefit greatly from AI technologies
• Example of how AI has been used to enhance repurposing of therapeutics for rare and orphan diseases
• Challenges and improvements to be successful in AL-directed drug repurposing

2:30 pm Case Study – Advancing Treatments in Oncology Through Repurposing Technology


• Improving the efficiency of the oncology development processes to create a more sustainable drug development paradigm
• Leveraging AI to develop new cancer treatments by accelerating the identification of promising treatments
• Applying evidence synthesis technology to help cancer patients who contract Covid-19 and quickly assess treatment choice

Getting Started With AI-Powered Drug Repurposing Projects

3:00 pm Panel Discussion – Overcoming the Challenges Faced When Converting Actionable Hypotheses into Meaningful Experimentation Work


• Discussing barrier to entry in starting a repurposing project: How much domain expertise is required to action a viable repurposing opportunity? Once predictions have been made, what do you do then?

3:45 pm Afternoon Networking Break

4:15 pm Case Study – Harnessing AI Tools in Drug Repurposing to Discover New Indications & Extend a Drugs Usage

  • David Hayes Director, Emergent Innovations, AstraZeneca


• Getting the basics right in setting up your methodology to discover new indications
• Critically examining AI techniques in drug repurposing
• Remaining mindful of the challenges that lie ahead; data quality, data heterogeneity, data sharing and access among companies, and interpretability of models

Patient Perspectives & Clinical Trials

4:45 pm Case Study – Strengthening POC Repurposing Trials Using AI


• Sharing examples when AI information has helped develop the POC clinical trial
• How this impacts the clinical trial review process and/or strengthens the likelihood of success of a POC trial

5:15 pm Fireside Chat – Patient Perspectives on Repurposing Discoveries


Addressing major considerations for the academics, healthcare institutions and companies in addressing patient needs and priorities

6:00 pm Chair’s Closing Remarks and End of Day 1